Brought to you by 
Ipsen and Roche to develop diabetes therapeutic; terminated
06 Sep 2011
Executive Summary
Following closely on their first co-development and co-promotion collaboration (signed in December 2002 for anticancer agents), Ipsen and Roche are again collaborating to develop Ipsen's BIM51077 glucagon-like peptide-1 (GLP-1) analog, which is now in Phase I clinical trials to treat Type II diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen and Roche to develop diabetes therapeutic; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice